Related Experiment Videos
Review of efficacy parameters
1Hôpital Laënnec, Paris, France.
The Annals of Thoracic Surgery
|July 1, 1998
Summary
Aprotinin use in pediatric cardiac surgery may reduce bleeding and inflammation, but more research is needed. Further trials are required to assess its effects on platelet preservation and determine optimal dosages for neonates.
Area of Science:
- Cardiovascular Surgery
- Pediatric Medicine
- Pharmacology
Background:
- Pediatric cardiopulmonary bypass (CPB) carries greater risks than in adults.
- Aprotinin is explored to mitigate CPB-induced complications by influencing hemostasis.
Purpose of the Study:
- To review existing literature on aprotinin's efficacy and safety in pediatric cardiac surgery.
- To identify gaps in current research regarding aprotinin use in this population.
Main Methods:
- Systematic literature review of studies on aprotinin in pediatric cardiac surgery.
- Analysis of study design, patient populations, and reported outcomes.
Main Results:
- Existing studies often lack placebo controls, have heterogeneous populations/procedures, and omit aprotinin plasma concentration data.
- Variations in dosing, heparin-protamine protocols, and CPB priming complicate result comparisons.
Conclusions:
- Further trials are essential to evaluate aprotinin's impact on platelet preservation, especially in neonates.
- Aprotinin may reduce fibrinolytic and platelet activation, offering clinical benefits in specific pediatric cardiac surgery patient groups.
- Optimal aprotinin dosages for specific objectives require further determination.